These drugs are efficacious in animal models, where they inhibit the p53–MDM2 interaction, thereby stabilizing p53 and allowing it to transcriptionally activate its downstream target genes to regulate cell cycle arrest, apoptosis and ultimately tumour suppression61. Here, TP53 is linked to neoplasm.